MARKET

OPK

OPK

Opko Health
NASDAQ
1.190
+0.020
+1.71%
After Hours: 1.190 0 0.00% 16:10 04/08 EDT
OPEN
1.200
PREV CLOSE
1.170
HIGH
1.220
LOW
1.185
VOLUME
2.91M
TURNOVER
--
52 WEEK HIGH
1.600
52 WEEK LOW
1.095
MARKET CAP
903.29M
P/E (TTM)
-3.9601
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
Reuters · 4h ago
BUZZ-U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
Reuters · 7h ago
BUZZ-OPKO Health rises as ModeX starts early trial of COVID-19 prevention antibody
Reuters · 7h ago
OPKO Health's ModeX Therapeutics Says First Participants Dosed In Phase 1 Clinical Trial Evaluating MDX2301 For Prevention Of COVID-19
Benzinga · 8h ago
Opko’s ModeX doses first patients in Phase 1 MDX2301 COVID-19 prevention trial
Reuters · 8h ago
Opko unit ModeX doses first patients in Phase 1 COVID-19 prevention trial MDX2301
Reuters · 8h ago
OPKO HEALTH’S MODEX THERAPEUTICS INITIATES CLINICAL TRIAL OF MDX2301 FOR THE PREVENTION OF COVID-19
Reuters · 8h ago
Weekly Report: what happened at OPK last week (0330-0403)?
Weekly Report · 2d ago
More
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Webull offers OPKO Health Inc stock information, including NASDAQ: OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.